ALEC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALEC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Days Inventory is also known as Days Sales of Inventory (DSI). Alector's Average Total Inventories for the three months ended in Dec. 2024 was $0.0 Mil. Alector's Cost of Goods Sold for the three months ended in Dec. 2024 was $0.0 Mil.
The historical rank and industry rank for Alector's Days Inventory or its related term are showing as below:
Alector's Days Inventory stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Alector's Inventory-to-Revenue for the three months ended in Dec. 2024 was 0.00.
The historical data trend for Alector's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alector Annual Data | |||||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | ||||||||||
Days Inventory | Get a 7-Day Free Trial |
![]() |
- | - | - | - | - |
Alector Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Days Inventory | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Alector's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Alector's Days Inventory distribution charts can be found below:
* The bar in red indicates where Alector's Days Inventory falls into.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Alector's Days Inventory for the fiscal year that ended in Dec. 2024 is calculated as
Days Inventory (A: Dec. 2024 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (A: Dec. 2023 ) | + | Total Inventories (A: Dec. 2024 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2024 ) | * | Days in Period |
= | ( (0 | + | 0) | / | 1 ) | / | 0 | * | 365 |
= | 0 | / | 0 | * | 365 | ||||
= | N/A |
Alector's Days Inventory for the quarter that ended in Dec. 2024 is calculated as:
Days Inventory (Q: Dec. 2024 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (Q: Sep. 2024 ) | + | Total Inventories (Q: Dec. 2024 )) | / | count ) | / | Cost of Goods Sold (Q: Dec. 2024 ) | * | Days in Period |
= | ( (0 | + | 0) | / | 1 ) | / | 0 | * | 365 / 4 |
= | 0 | / | 0 | * | 365 / 4 | ||||
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alector (NAS:ALEC) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Alector's Inventory Turnover for the three months ended in Dec. 2024 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Alector's Inventory to Revenue for the three months ended in Dec. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 0 | / | 54.24 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Thank you for viewing the detailed overview of Alector's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Sara Kenkare-mitra | officer: President and Head of R&D | C/O ALECTOR, INC, 131 OYSTER POINT BLVD, SUITE 600, SOUTH SAN FRANCISCO CA 94080 |
Gary Romano | officer: Chief Medical Officer | TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103 |
Arnon Rosenthal | director, officer: Chief Executive Officer | C/O ALECTOR, INC., 151 OYSTER POINT BLVD., #300, SOUTH SAN FRANCISCO CA 94080 |
Marc Grasso | officer: Chief Financial Officer | C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO CA 92121 |
Richard H Scheller | director | C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990 |
Paula Hammond | director | C/O ALECTOR, INC., 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA 94080 |
Kristine Yaffe | director | C/O ALECTOR, INC., 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO CA 94080 |
Polaris Venture Management Co. Vi, L.l.c. | 10 percent owner | ONE MARINA PARK DRIVE, 8TH FLOOR, BOSTON MA 02210 |
Terrance Mcguire | director, 10 percent owner | C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154 |
Elizabeth A. Garofalo | director | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
David M. Wehner | director | C/O FACEBOOK, INC., 1601 WILLOW ROAD, MENLO PARK CA 94025 |
Tillman U. Gerngross | director | C/O ARSANIS, INC., 890 WINTER STREET, SUITE 230, WALTHAM MA 02451 |
Lavigne Louis J Jr | director | C/O ALLERGAN, INC., 2525 DUPONT DRIVE, IRVINE CA 92612 |
Robert King | officer: Chief Development Officer | 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404 |
Shehnaaz Suliman | officer: President and COO | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By GuruFocus News • 11-13-2024
By GuruFocus News • 11-07-2024
By GlobeNewswire • 07-28-2024
By GuruFocus News • 12-07-2024
By GuruFocus News • 12-02-2024
By Marketwired • 08-07-2024
By Marketwired • 06-20-2024
By Marketwired • 02-19-2025
By GuruFocus Research • 08-09-2024
By Marketwired • 11-14-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.